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Abstract
Background: Cyclooxygenase (COX)-2 has been implicated in tumour progression, angiogenesis and
metastasis in non-small cell lung cancer (NSCLC). We speculated that inhibition of COX-2 activity might
reduce expression of the pro-angiogenic factors vascular endothelial growth factor (VEGF) and
interleukin-8 (IL-8) in lung cancer cells.
Methods: The levels of IL-8, VEGF and prostaglandin E2 (PGE2) were measured by ELISA. Expression of
COX-1 and COX-2 was determined by Western blotting. Inhibition or knockdown of COX-2 was
achieved by treating NSCLC cells with specific COX-2 inhibitor NS-398 or COX-2 siRNA, respectively.
Results: We found that NSCLC cell lines produced more IL-8 than VEGF (p < 0.001). In contrast, small
cell lung cancer (SCLC) cell lines produced more VEGF than IL-8 (p < 0.001). COX-1 was expressed in all
cell lines, but COX-2 was expressed only in NSCLC cell lines. Consistent with this, PGE2 was significantly
higher in NSCLC cell lines than SCLC cell lines (p < 0.001). We tested these cell lines with a potent specific
COX-2 inhibitor NS-398 at concentrations of 0.02, 0.2, 2, 20 μM for 24 or 48 h. The COX-2 activity was
reduced in a dose-dependent fashion as shown by reduced PGE2 production. VEGF was significantly
reduced following the treatment of NS-398 in A549 (by 31%) and MOR/P (by 47%) cells lines which
expressing strong COX-2, but not in H460 cell line which expressing very low COX-2. However, IL-8 was
not reduced in these cell lines. To confirm these results, we knocked down COX-2 expression with COX-
2 siRNA in these cell lines. VEGF was significantly decreased in A549 (by 24%) and in MOR/P (by 53%),
but not in H460 whereas IL-8 was not affected in any cell line.
Conclusion: We conclude that NSCLC cells produce much higher levels of IL-8 than SCLC cells whereas
both NSCLC and SCLC cells produce similar levels of VEGF. COX-2 is only expressed in NSCLC cells,
but not in SCLC cells. VEGF is produced in both NSCLC and SCLC cells regardless of COX-2 expression.
However, VEGF production is, at least partly, COX-2 dependent in NSCLC cells expressing COX-2. In
contrast, IL-8 production is COX-2 independent in both NSCLC and SCLC cells. We speculate that
combined targeting of COX-2 and IL-8 may be useful in the treatment of patients with NSCLC and
targeting VEGF may be useful in the treatment of patients with SCLC.
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Background
Lung cancer remains the leading cause of cancer death in
many countries worldwide. There is considerable interest
in anti-angiogenic drugs as therapeutic agents for lung
cancer. Angiogenesis in tumours is promoted through the
secretion of a variety of pro-angiogenic factors. Among
these, vascular endothelial growth factor (VEGF) is impor-
tant in many tumour types due to both its potent activity
and markedly elevated expression level. Several studies
have shown that high levels of VEGF are associated with
increased tumour vascularity, advanced stage and poor
prognosis in patients with non-small cell (NSCLC) and
small cell lung cancer (SCLC) [1-5]. In addition to its ang-
iogenic effects, functional VEGF receptors are expressed
on SCLC cells and VEGF induces cell proliferation and
migration in these cells [6]. Treatment with a humanized
monoclonal antibody to VEGF, bevacizumab (Avastin),
prolongs the survival of patients with NSCLC [7].
Interleukin-8 (IL-8), one of the ELR+ CXC family of chem-
okines, is another potent pro-angiogenic factor and its
expression is associated with angiogenesis, tumour pro-
gression and survival in patients with NSCLC [8-11]. In
addition to its angiogenic effects, IL-8 receptors (CXCR1
and CXCR2) are expressed on lung cancer cells and IL-8
can act as growth/survival factor to these cells [12]. Hence,
both VEGF and IL-8 contribute to lung cancer progression
through angiogenic and direct mitogenic effects [13,14].
The relative contributions of different angiogenic factors
to lung cancer growth are unknown.
Cyclooxygenases (COX) are key enzymes in the conver-
sion of arachidonic acid to prostaglandin (PG) and other
eicosanoids including PGE2, PGD2, PGF2α, PGI2  and
thromboxane A2. COX-1 is present in nearly all cells
whereas COX-2 is normally undetectable but is inducible
under circumstances such as inflammation and cancer.
Cancer cells, including NSCLC cells, express high levels of
COX-2 protein [15-17]. COX-2 overexpression has been
associated with poor prognosis in NSCLC, although a
recent meta-analysis challenges this [18]. It is correlated to
VEGF and IL-8 expression in NSCLC [19,20]. Selective
COX-2 inhibitors have been shown to inhibit the growth
and metastasis of several types of cancers [21]. Celecoxib
(Celebrex) and rofecoxib (Vioxx) have been tested in clin-
ical trials, but their utilities are limited by cardiac adverse
effects. Nevertheless, COX-2 could be a potential target to
limit lung cancer growth. However, the mechanism
underlying inhibition of angiogenesis and metastasis by
targeting COX-2 is not fully understood. The aim of this
study was to establish whether there is a direct relation-
ship between COX-2 expression and VEGF and IL-8 pro-
duction in lung cancer cells.
Methods
Lung cancer cell lines, cell culture and reagents
The lung cancer cell lines used were A549, H460, MOR/P
(NSCLC) and GLC19, H69, H345, H711, Lu165 (SCLC).
All cell lines were grown in RPMI 1640 (Bio Whittaker)
with 10% fetal calf serum (Biosera) at 37°C in 5% CO2,
95% air. To collect supernatants for VEGF and IL-8 detec-
tion, NSCLC (adherent) cells were seeded in 6 well tissue
culture plates and SCLC (suspension) cells were seeded in
24 well plates before being treated with various concentra-
tions of the COX-2 inhibitor NS-398 (Cayman Chemical
and Calbiochem) in triplicate for 24 h or 48 h. Anti-COX-
1 and anti-COX-2 antibodies were purchased from Cay-
man Chemical. Anti-actin antibody was purchased from
Sigma. Antibodies to VEGF and IL-8 for ELISA were pur-
chased from R&D systems. PGE2 enzyme immunoassay
kit was purchased from R&D systems. The siRNA-COX-2
and siRNA-control were purchased from Dharmacon.
Enzyme-linked immunosorbent assay (ELISA)
Total VEGF and IL-8 concentrations were determined by
ELISA kits as previously described for IL-8 [12]. PGE2 was
measured using a highly sensitive PGE2 competitive ELISA
kit according to the manufacturer's instruction. The inten-
sity of colour developed was measured using a Dynatech
MR5000 microplate reader at 450 nm optical density
(OD) with correction at 570 nm.
Western blotting
Whole cell lysates were prepared by resuspending cell pel-
lets in CelLytic™M lysis buffer (Sigma) and incubating on
ice for 15 minutes before centrifuging at 13,000 rpm for
15 minutes. Protein concentrations were measured in
triplicate with the quick start Bradford reagent (Bio-Rad),
and 20 μg of protein was added to loading buffer (62.5
mM Tris.HCl pH 6.8, 2% SDS, 10% glycerol, 50 mM DTT
and 0.01% bromophenol blue), boiled, and electro-
phoresed on a 12% polyacrylamide/SDS gel, before being
transferred to a Hybond P membrane (Amersham Bio-
sciences). Membranes were incubated in primary anti-
COX-2 (1:1000 dilution) or anti-COX-1 antibody (1:200
dilution) for 2 h at room temperature with gentle agita-
tion, and in peroxidase-conjugated rabbit anti-mouse IgG
for 2 hour at room temperature before being treated with
the ECL detection system and exposed to hyperfilm ECL
film (Amersham Biosciences). In some experiments, the
membranes were washed and re-probed with anti-actin
antibody as control of equal loading.
Cell growth assay
Cell growth was determined by direct cell counting under
the microscope after cells were treated with various con-
centration of NS-398 for 24 or 48 h. The cells were
trypsinized and resuspended in PBS. 50 μl of cell suspen-
sion was added to 50 μl of 0.4% Trypan Blue solution,BMC Cancer 2008, 8:218 http://www.biomedcentral.com/1471-2407/8/218
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mixed thoroughly and left for 10 min. Viable cells and
dead cells (staining blue) were counted in four 1 mm cor-
ner squares of a hemocytometer slide. Total cells = (aver-
age count/square) × (dilution factor) × 104 × (predilution
volume).
siRNA transfection
On-target COX-2 plus SMARTpool (COX-2 siRNA) and
SiCONTROL Non-Targeting siRNA#1 (control siRNA)
were purchased from Dharmacon. The sequences of On-
target COX-2 plus SMARTpool (COX-2 siRNA) [GenBank:
NM_000963] were GGACUUAUGGGUAAUGUUAUU
(duplex 6); GAUAAUUGAUGGAGAGAUGUU (duplex
7); GUGAAACUCUGGCUAGACAUU (duplex 8) and
CGAAAUGCAAUUAUGAGUUUU (duplex 9). The siR-
NAs were transfected into the cells in 12-well plate using
DharmaFECT1 transfection reagent according to manu-
facturer's instructions. Four hours after transfection, the
media was replaced by fresh media with 10% FCS. After
further 48 h, the media were collected for ELISA and cells
were collected for protein extraction.
Statistical analysis
The results were expressed as mean ± standard error of the
mean (SEM). Statistical significance was obtained using
unpaired student's t-test. Each experiment was repeated at
least 3 times. Values with p < 0.05 were considered signif-
icant.
Results
IL-8 and VEGF production in NSCLC and SCLC cell lines
IL-8 and VEGF were detected by ELISA in conditioned
medium after 48 h incubation in a panel of lung cancer
cell lines (Figure 1). In all three tested NSCLC cell lines,
IL-8 production was significantly (p < 0.001) higher than
VEGF production. In contrast, VEGF production was sig-
nificantly (p < 0.001) higher than IL-8 production in all
five tested SCLC cell lines. NSCLC cell lines consistently
produced higher levels of IL-8 (above 5.6 ng/ml/106cells)
than SCLC cell lines (under 0.9 ng/ml/106cells). However,
there was no significant difference in VEGF levels between
NSCLC (ranging from 3.7 to 6.3 ng/ml/106cells) and
SCLC (ranging from 4.0 to 11.2 ng/ml/106cells) cell lines.
COX-1 and COX-2 expression and PGE2 production in 
lung cancer cell lines
Expression of COX-1 and COX-2 by a panel of lung cancer
cells was determined by Western blotting. COX-1 was
expressed at similar intensity in all NSCLC and SCLC cell
lines. In contrast, COX-2 was expressed in all 3 NSCLC
cell lines but none of 5 SCLC cell lines. Strong COX-2
expression was seen in MOR/P and A549 cell lines and
weak COX-2 was present in H460 cell lines (Figure 2A).
The level of PGE2 production was measured by competi-
tive ELISA. NSCLC cell lines produced significantly higher
levels of PGE2(mean 1001 pg/ml/106cells) than SCLC cell
lines (mean: 18 pg/ml/106cells, p < 0.001) (Figure 2B).
Effects of COX-2 inhibition on production of VEGF and IL-
8
NS-398 is a potent and specific COX-2 inhibitor [22]. To
confirm that NS-398 effectively targeted COX-2 in the
NSCLC cell lines, we measured PGE2 production by ELISA
and found that it was reduced in a dose-dependent fash-
ion by NS-398 at 48 h treatment in A549. PGE2 was
reduced to 390 pg/ml (p < 0.05) by NS-398 at 2 μM and
to 105 pg/ml (p < 0.01) by NS-398 at 20 μM from 937 pg/
ml, respectively (Figure 3B). At 24 h treatment, PGE2 was
significantly (p < 0.01) reduced by NS-398 (20 μM) at 24
h in all three tested cell lines (Figure 3C). COX-2 expres-
sion was not changed by NS-398 at up to 2 μM, and
slightly reduced by NS-398 at 20 μM as shown by Western
blotting, whereas COX-1 was not affected (Figure 3A).
IL-8 and VEGF production in lung cancer cell lines Figure 1
IL-8 and VEGF production in lung cancer cell lines. 
(A). IL-8 protein was measured by ELISA in 48 h conditioned 
medium of a panel of NSCLC (A549, H460 and MOR/P) and 
SCLC (H69, H345, H711, GLC19 and Lu165) cell lines. (B). 
VEGF production was measured by ELISA in the same 
medium of these cell lines. Each bar is the mean ± SEM of 
three determinations from three independent experiments.
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To determine whether inhibition of COX-2 affects VEGF
and IL-8 production, we treated lung cancer cell lines with
various concentrations (0, 0.02, 0.2, 2 and 20 μM) of NS-
398 for 24 or 48 h. As expected, NS398 had no effect in
SCLC cell lines, which do not express COX-2 (data not
shown). However, VEGF production was significantly
reduced by NS-398 at 20 μM in A549 (-31%, p < 0.05) and
MOR/P (-47%, p < 0.05) cells although VEGF expression
was not changed in H460 cells. VEGF was slightly reduced
by NS-398 at 2 μM in A549 (-16%, p > 0.05) and MOR/P
(-17%, p < 0.05). In contrast, IL-8 production was not
reduced by NS-398 in these NSCLC cell lines (Figure 4A,
4B and 4C).
To test whether sublethal concentrations of NS-398 used
in this study inhibited cell proliferation, we counted cell
number using Trypan Blue stain and the Hemocytometer
after lung cancer cells were treated with NS-398 for 24 h.
There was no significant inhibition of cell growth in any
of the 3 NSCLC cell lines at concentrations up to 20 μM of
NS-398 (Figure 5).
Effects of COX-2 knockdown on production of VEGF and 
IL-8
To further confirm the direct involvement of COX-2 on
expression of these factors, we treated NSCLC cell lines
with COX-2 siRNA for 48 h. The endogenous COX-2 was
markedly knocked down by COX-2 siRNA in all tested cell
lines (Figure 6A). Consistent with previous findings with
NS-398, IL-8 production was not decreased in any of these
tested cell lines (Figure 6B). VEGF was significantly
reduced by COX-2 siRNA in A549 (-24%, p < 0.05) and in
MOR/P (-53%, p < 0.05), but not in H460 cell line (Figure
6C).
Expression of COX-1, COX-2 and PGE2 in lung cancer cell lines Figure 2
Expression of COX-1, COX-2 and PGE2 in lung cancer cell lines. (A). Expression of COX-1 and COX-2 by a panel of 
lung cancer cell lines was determined by Western blotting. 30 μg of total protein was loaded from each sample. These results 
are representative of three independent experiments (B). PGE2 production was measured in 48 h conditioned medium by com-
petitive ELISA. Each bar is the mean ± SEM of three determinations.
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Effects of NS-398 on expression of COX-1, COX-2 and PGE2 Figure 3
Effects of NS-398 on expression of COX-1, COX-2 and PGE2. (A). COX-1 and COX-2 expression in MOR/P cells was 
detected by Western blotting after incubation for 24 h with NS-398 at concentration of 0–20 μM. (B). PGE2 production was 
measured by ELISA in A549 cell line after treatment with NS-398 2 μM (stripe bar) and 20 μM (solid bar) for 48 h, or control 
(open bar). (C). PGE2 production was measured by ELISA in three NSCLC cell lines after treatment with NS-398 20 μM (solid 
bar) for 24 h, or control (open bar). Each bar is the mean ± SEM of three determinations. ** P < 0.01.
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Effects of COX-2 inhibition on production of VEGF (solid bar) and IL-8 (open bar) in NSCLC cell lines (A) A549, (B) H460 and  (C) MOR/P Figure 4
Effects of COX-2 inhibition on production of VEGF (solid bar) and IL-8 (open bar) in NSCLC cell lines (A) 
A549, (B) H460 and (C) MOR/P. Lung cancer cells were treated with various concentrations (0, 0.02, 0.2, 2 and 20 μM) of 
NS-398 for 48 h. Each bar is the mean ± SEM of three determinations from two independent experiments. * P < 0.05.
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Discussion
Several studies have shown that COX-2, VEGF and IL-8 are
overexpressed in lung cancer compared to normal bron-
chial epithelium. Most studies have focused on NSCLC
since clinical specimens of SCLC are difficult to obtain for
research because SCLC patients are rarely operated on. Tas
et al [23,24] recently reported that serum VEGF levels were
significantly higher in lung cancer patients than healthy
controls. Mean serum VEGF levels appeared to be slightly
higher in SCLC (1350 pg/ml, range 170 – 3810 pg/ml, n
= 34) than NSCLC patients (402 pg/ml, range 121 – 1800
pg/ml, n = 52), but this was not tested statistically.
Here, we have compared and contrasted SCLC and
NSCLC using a panel of cell lines. Basal expression of
VEGF, IL-8, COX-1, COX-2 and PGE2 was determined in
three NSCLC and five SCLC cell lines. VEGF was produced
at similar levels in all cell lines. NSCLC cell lines produced
much more IL-8 than SCLC cell lines. COX-1 was
expressed at similar levels in all cell lines, whereas COX-2
was only expressed in NSCLC cell lines, albeit at low levels
in H460. Interestingly, high levels of PGE2 were not only
produced in MOR/P and A549 cell lines as a result of
strong COX-2 expression, but also in H460 cell line in
which COX-2 expression was weak. This could result from
reduced catabolism of PGE2 due to low levels of 15-
hydroxyprostaglandin dehydrogenase (15-PGDH), a pri-
mary enzyme responsible for PGE2 metabolism [25]. Pre-
vious studies showed that NSCLC cells expressed COX-2
protein [17,26]. However, one study showed that a subset
of 20% of SCLC patients (11 out of 54) expressed COX-2
[27]. These data, together with our results and those of
Pold et al [20], appear to suggest an association between
COX-2 expression and IL-8 production in lung cancer
cells. In contrast, VEGF production did not seem to be
solely related to COX-2 expression as both COX-2 positive
and negative cell lines produced similar levels of VEGF in
our study.
COX-2 expression has previously been associated with
VEGF in patients with NSCLC [19,20]. Two reports from
Dubinett's lab showed that expressions of IL-8 and VEGF
were enhanced in NSCLC cell lines transfected with retro-
viral COX-2 vector [20,28]. The aim of this study was to
exam the causal relationship between COX-2 and IL-8 or
VEGF in lung cancer cell through inhibition of endog-
enous COX-2 using either a potent and specific COX-2
inhibitor, NS398 or COX-2 siRNA. NSCLC cell lines were
incubated with NS-398 for 24 h and 48 h. NS-398 exerts
its effects by directly inhibits COX-2 activity. We demon-
strated that COX-2 activity was inhibited by NS-398 as
evidence of reduced production of PGE2 in these cell lines.
We decided to use a maximum concentration of 20 μM in
this study because COX-2 inhibition had been demon-
strated and cell growth was not significantly inhibited in
NSCLC cell lines as shown in Figure 5 at this level. NS-398
has been shown to induce 16% apoptosis in H460 cells at
300 μM in another study [29]. Unexpectedly, IL-8 produc-
tion was not altered after treatment with NS-398 in these
cell lines. However, VEGF was significantly decreased by
NS-398 in A549 and MOR/P cell lines, but not in H460.
Both of A549 and MOR/P cell lines expressed high levels
of COX-2 whereas H460 expressed very low level of COX-
2 in our experiments. In some reports, H460 was consid-
ered as COX-2-negative cell line [29]. These results sug-
gested that VEGF production was independent of COX-2
in H460 and other COX-2-negative cells such as SCLC cell
lines. We further confirm the direct involvement of COX-
2 on VEGF production using COX-2 siRNA, and similar
results were found. VEGF was significantly reduced in
both of A549 and MOR/P, but not in H460. IL-8 was not
affected following treatment with COX-2 siRNA in all
tested NSCLC cell lines. These results suggest that VEGF is,
at least partly, COX-2 dependent in COX-2-expressing
NSCLC cells such as A549 and MOR/P. This finding is in
agreement with other findings [19,20,28,30]. However,
VEGF production is clearly not depend on COX-2 status in
other lung cancer cells such as SCLC cells, which express-
ing no COX-2, and some NSCLC cells including H460,
which expressing very low level of COX-2. Our results also
suggest that IL-8 is COX-2 independent in lung cancer
cells. This finding seems to contradict others [28]. The dif-
ferent findings may be due to the different experiments
systems (e.g. to introduce ectopic overexpression of COX-
2 or to knock down endogenous COX-2 by siRNA)
Effects of COX-2 inhibition on NSCLC cell growth Figure 5
Effects of COX-2 inhibition on NSCLC cell growth. 
Lung cancer cells from three NSCLC cell lines were treated 
with various concentrations (0, 0.02, 0.2, 2 and 20 μM) of 
NS-398 for 48 h. Cell numbers were counted by direct cell 
counting using Trypan Blue stain and the Hemocytometer. 
Each bar is the mean ± SEM of three determinations from 
two independent experiments.
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Effects of COX-2 knockdown on production of VEGF and IL-8 in NSCLC cell lines A549, H460 and MOR/P Figure 6
Effects of COX-2 knockdown on production of VEGF and IL-8 in NSCLC cell lines A549, H460 and MOR/P. 
Lung cancer cells were transfected with COX-2 siRNA or control siRNA for 48 h. (A) Expression of COX-2 and actin was 
detected following transfection for 48 h by Western blotting. (B) IL-8 production was measured by ELISA following transfec-
tion of either COX-2 siRNA (solid bar) or control siRNA (open bar). (C) VEGF production was detected by ELISA following 
transfection of either COX-2 siRNA (solid bar) or control siRNA (open bar). Each bar is the mean ± SEM of three determina-
tions. * P < 0.05.
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employed in these studies. Interestingly, Raut et al [31]
reported that blocking COX-2 production by NS-398 in
pancreatic cancer cell lines did not affect VEGF, bFGF and
IL-8 production, but Singh et al [32] found that NS-398
downregulated IL-8 by 30% in a COX-2 transfected MDA-
231 breast cancer cell line. These contradictory findings
suggest that the relationship between COX-2, VEGF and
IL-8 is complex. More studies are required to establish the
causal relationship between COX-2 and IL-8 and VEGF in
lung cancer. COX-2 inhibitors have been shown to reduce
angiogenesis and metastasis in lung cancer [21], our
results suggest that anti-angiogenic effects of COX-2
inhibitors might be, at least partly, mediated by inhibition
of VEGF, but not IL-8. As IL-8 seems to be independent of
COX-2, therefore, there is a strong rationale for combin-
ing treatments with inhibitors of COX-2 and IL-8 in
NSCLC.
Conclusion
Our results suggest that NSCLC cells produce much more
IL-8 than SCLC cells whereas both NSCLC and SCLC cells
produce similar levels of VEGF. COX-2 is only expressed
in NSCLC cells, but not in SCLC cells. VEGF can be pro-
duced in lung cancer cells regardless of COX-2 expression.
However, VEGF production is, at least partly, COX-2
dependent in NSCLC cells expressing COX-2. In contrast,
IL-8 production is COX-2 independent in both NSCLC
and SCLC cells. We speculate that combined targeting of
COX-2 and IL-8 may be useful in the treatment of patients
with NSCLC and targeting VEGF may be useful in the
treatment of patients with SCLC.
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